Advanced Endometrial Cancer Recruiting Phase 2 Trials for Anlotinib (DB11885)

IndicationStatusPhase
DBCOND0050728 (Advanced Endometrial Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05481645Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.Treatment
NCT04574284A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial CancerTreatment